Literature DB >> 24795837

Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.

Antoinette de Jong1, Thomas C Kwee1, John M H de Klerk2, Judit A Adam3, Bart de Keizer1, Rob Fijnheer4, Marie José Kersten5, Inge Ludwig6, Yvonne W S Jauw7, Josée M Zijlstra7, Indra C Pieters-Van den Bos8, Jaap Stoker9, Otto S Hoekstra10, Rutger A J Nievelstein1.   

Abstract

The purpose of this study was to determine the correlation between the (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) standardized uptake value (SUV) and the diffusion-weighted magnetic resonance imaging (MRI) apparent diffusion coefficient (ADC) in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Pretreatment FDG-PET and diffusion-weighted MRI of 21 patients with histologically proven DLBCL were prospectively analyzed. In each patient, maximum, mean and peak standardized uptake value (SUV) was measured in the lesion with visually highest FDG uptake and in the largest lesion. Mean ADC (ADCmean, calculated with b-values of 0 and 1000 s/mm(2)) was measured in the same lesions. Correlations between FDG-PET metrics (SUVmax, SUVmean, SUVpeak) and ADCmean were assessed using Pearson's correlation coefficients. In the lesions with visually highest FDG uptake, no significant correlations were found between the SUVmax, SUVmean, SUVpeak and the ADCmean (P=0.498, P=0.609 and P=0.595, respectively). In the largest lesions, there were no significant correlations either between the SUVmax, SUVmean, SUVpeak and the ADCmean (P=0.992, P=0.843 and P=0.894, respectively). The results of this study indicate that the glycolytic rate as measured by FDG-PET and changes in water compartmentalization and water diffusion as measured by the ADC are independent biological phenomena in newly diagnosed DLBCL. Further studies are warranted to assess the complementary roles of these different imaging biomarkers in the evaluation and follow-up of DLBCL.

Entities:  

Keywords:  FDG-PET; apparent diffusion coefficient; diffuse large B-cell lymphoma; diffusion-weighted MRI; standardized uptake value

Year:  2014        PMID: 24795837      PMCID: PMC3999403     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  20 in total

1.  Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Taoufik El-Gnaoui; Alexandre Vignaud; Pauline Beaussart; Shih-jui Lin; Karim Belhadj; Pierre Brugières; Eva Evangelista; Corinne Haioun; Michel Meignan; Alain Rahmouni
Journal:  Eur Radiol       Date:  2010-03-23       Impact factor: 5.315

2.  Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.

Authors:  Dominique Delbeke; Sigrid Stroobants; Eric de Kerviler; Christian Gisselbrecht; Michel Meignan; Peter S Conti
Journal:  Oncologist       Date:  2009

3.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; U Vitolo; J Walewski; M Gomes da Silva; O Shpilberg; M André; M Pfreundschuh; M Dreyling
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study.

Authors:  Xingchen Wu; Hannu Pertovaara; Prasun Dastidar; Martine Vornanen; Lassi Paavolainen; Varpu Marjomäki; Ritva Järvenpää; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Eur J Radiol       Date:  2012-12-17       Impact factor: 3.528

5.  Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.

Authors:  Shonit Punwani; Stuart A Taylor; Alan Bainbridge; Vineet Prakash; Steven Bandula; Enrico De Vita; Oystein E Olsen; Sharon F Hain; Nicola Stevens; Stephen Daw; Ananth Shankar; Jamshed B Bomanji; Paul D Humphries
Journal:  Radiology       Date:  2010-04       Impact factor: 11.105

6.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

Authors:  Tae Min Kim; Jin Chul Paeng; In Kook Chun; Bhumsuk Keam; Yoon Kyung Jeon; Se-Hoon Lee; Dong-Wan Kim; Dong Soo Lee; Chul Woo Kim; June-Key Chung; Il Han Kim; Dae Seog Heo
Journal:  Cancer       Date:  2012-12-04       Impact factor: 6.860

7.  Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.

Authors:  Velasco Stéphane; Burg Samuel; Delwail Vincent; Guilhot Joelle; Perdrisot Remy; Guilhot Gaudeffroy Francois; Tasu Jean-Pierre
Journal:  Eur J Radiol       Date:  2013-08-09       Impact factor: 3.528

8.  Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography.

Authors:  Thomas C Kwee; Henriette M E Quarles van Ufford; Frederik J Beek; Taro Takahara; Cuno S Uiterwaal; Marc B Bierings; Inge Ludwig; Rob Fijnheer; Rutger A J Nievelstein
Journal:  Invest Radiol       Date:  2009-10       Impact factor: 6.016

9.  On the added value of baseline FDG-PET in malignant lymphoma.

Authors:  Henriette Quarles van Ufford; Otto Hoekstra; Marie de Haas; Rob Fijnheer; Shulamiet Wittebol; Bianca Tieks; Mark Kramer; John de Klerk
Journal:  Mol Imaging Biol       Date:  2009-10-07       Impact factor: 3.488

10.  Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.

Authors:  Yukihiro Miyazaki; Yuichiro Nawa; Masao Miyagawa; Sumiko Kohashi; Koichi Nakase; Masaki Yasukawa; Masamichi Hara
Journal:  Ann Hematol       Date:  2012-10-19       Impact factor: 3.673

View more
  4 in total

1.  Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.

Authors:  Asim Afaq; Francesco Fraioli; Harbir Sidhu; Simon Wan; Shonit Punwani; Shih-Hsin Chen; Oguz Akin; David Linch; Kirit Ardeshna; Jonathan Lambert; Kenneth Miles; Ashley Groves; Irfan Kayani
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

2.  18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.

Authors:  Chiara Giraudo; Markus Raderer; Georgios Karanikas; Michael Weber; Barbara Kiesewetter; Werner Dolak; Ingrid Simonitsch-Klupp; Marius E Mayerhoefer
Journal:  Invest Radiol       Date:  2016-03       Impact factor: 6.016

Review 3.  Meta-Analysis of the Correlation between Apparent Diffusion Coefficient and Standardized Uptake Value in Malignant Disease.

Authors:  Shengming Deng; Zhifang Wu; Yiwei Wu; Wei Zhang; Jihui Li; Na Dai; Bin Zhang; Jianhua Yan
Journal:  Contrast Media Mol Imaging       Date:  2017-02-26       Impact factor: 3.161

4.  Geometrical Comparison and Quantitative Evaluation of 18F-FDG PET/CT- and DW-MRI-Based Target Delineation Before and During Radiotherapy for Esophageal Squamous Carcinoma.

Authors:  Huimin Li; Jianbin Li; Fengxiang Li; Yingjie Zhang; Yankang Li; Yanluan Guo; Liang Xu
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.